索拉非尼联合肝动脉灌注奥沙利铂、氟尿嘧啶和亚叶酸钙对比索拉非尼单药治疗合并门静脉侵犯的肝细胞癌:一项随机临床试验
这项随机、开放标签临床试验在5家中国医院纳入247例合并门静脉侵犯的肝细胞癌患者,1:1随机接受索拉非尼联合HAIC(FOLFOX方案)或索拉非尼单药。联合组中位总生存13.37个月 vs 单药组7.13个月(HR 0.35,95%CI 0.26-0.48,P<.001),缓解率51例(40.8%)vs 3例(2.46%),中位无进展生存7.03个月 vs 2.6个月(P<.001)。
要点
- 索拉非尼联合HAIC较索拉非尼单药延长中位总生存(13.37 vs 7.13个月,HR 0.35)。
- 联合组缓解率40.8% vs 2.46%,中位无进展生存7.03 vs 2.6个月。
- 联合组3/4级中性粒细胞减少、血小板减少和呕吐较单药组更常见。
核心结论
- 在合并门静脉侵犯的肝细胞癌患者中,索拉非尼联合HAIC(FOLFOX方案)较索拉非尼单药改善总生存,且毒性可接受。
研究设计与样本
- 随机、开放标签临床试验,在中国5家医院于2016年4月1日至2017年10月10日入组,随访10个月。
- 筛查818例,247例合并门静脉侵犯的肝细胞癌患者按1:1计算机生成序列随机分配至索拉非尼联合HAIC组或索拉非尼组。
- 主要终点为意向性治疗分析的总生存,安全性在至少接受1剂研究治疗的患者中评估。
主要发现
- 247例患者中位年龄49岁(范围18-75岁),男性223例、女性24例。
- 中位总生存:SoraHAIC组13.37个月(95%CI 10.27-16.46)vs 索拉非尼组7.13个月(95%CI 6.28-7.98),HR 0.35(95%CI 0.26-0.48),P<.001。
- 缓解率:SoraHAIC组51例(40.8%)vs 索拉非尼组3例(2.46%),P<.001。
- 中位无进展生存:SoraHAIC组7.03个月(95%CI 6.05-8.02)vs 索拉非尼组2.6个月(95%CI 2.15-3.05),P<.001。
- 3/4级不良事件中,SoraHAIC组较索拉非尼组更常见的有中性粒细胞减少(12例[9.68%] vs 3例[2.48%])、血小板减少(16例[12.9%] vs 6例[4.96%])和呕吐(8例[6.45%] vs 1例[0.83%])。
关键数值与推荐
- 索拉非尼组:索拉非尼400 mg每日两次。
- SoraHAIC组:索拉非尼400 mg每日两次联合HAIC(奥沙利铂85 mg/m2、亚叶酸钙400 mg/m2、第1天氟尿嘧啶推注400 mg/m2、氟尿嘧啶持续输注2400 mg/m2共46小时,每3周一次)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit. Sorafenib plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) has shown promising results for these patients in a previous phase 2 study. OBJECTIVE: To investigate the efficacy and safety of sorafenib plus HAIC compared with sorafenib for hepatocellular carcinoma with portal vein invasion. DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label clinical trial enrolled 818 screened patients. Of the 818 participants, 247 with hepatocellular carcinoma and portal vein invasion were randomly assigned (1:1) via a computer-generated sequence to receive sorafenib plus HAIC or sorafenib. This trial was conducted at 5 hospitals in China and enrolled patients from April 1, 2016, to October 10, 2017, with a follow-up period of 10 months. INTERVENTIONS: Randomization to receive 400 mg sorafenib twice daily (sorafenib group) or 400 mg sorafenib twice daily plus HAIC (SoraHAIC group) (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2 on day 1, and fluorouracil infusion 2400 mg/m2 for 46 hours, every 3 weeks). MAIN OUTCOMES AND MEASURES: The primary endpoint was overall survival by intention-to-treat analysis. Safety was assessed in patients who received at least 1 dose of study treatment. RESULTS: For 247 patients (median age, 49 years; range, 18-75 years; 223 men and 24 women), median overall survival was 13.37 months (95% CI, 10.27-16.46) in the SoraHAIC group vs 7.13 months (95% CI, 6.28-7.98) in the sorafenib group (hazard ratio [HR], 0.35; 95% CI, 0.26-0.48; P < .001). The SoraHAIC group showed a higher response rate than the sorafenib group (51 [40.8%] vs 3 [2.46%]; P < .001), and a longer median progression-free survival (7.03 [95% CI, 6.05-8.02] vs 2.6 [95% CI, 2.15-3.05] months; P < .001). Grade 3/4 adverse events that were more frequent in the SoraHAIC group than in the sorafenib group included neutropenia (12 [9.68%] vs 3 [2.48%]), thrombocytopenia (16 [12.9%] vs 6 [4.96%]), and vomiting (8 [6.45%] vs 1 [0.83%]). CONCLUSIONS AND RELEVANCE: Sorafenib plus HAIC of FOLFOX improved overall survival and had acceptable toxic effects compared with sorafenib in patients with hepatocellular carcinoma and portal vein invasion. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02774187.
引用
- He M, Li Q, Zou R, et al. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 31070690. doi:10.1001/jamaoncol.2019.0250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。